Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
ACTIVE_NOT_RECRUITING
Status
Conditions
- Anatomic Stage III Breast Cancer AJCC v8
- Anatomic Stage IV Breast Cancer AJCC v8
- BRCA-Associated Malignant Neoplasm
- BRCA Hereditary Ovarian Carcinoma
- Metastatic BRCA Hereditary Breast Carcinoma
- Metastatic Breast Carcinoma
- Metastatic Fallopian Tube Carcinoma
- Metastatic Malignant Solid Neoplasm
- Metastatic Ovarian Carcinoma
- Metastatic Pancreatic Carcinoma
- Metastatic Primary Peritoneal Carcinoma
- Prognostic Stage III Breast Cancer AJCC v8
- Prognostic Stage IV Breast Cancer AJCC v8
- Stage III Fallopian Tube Cancer AJCC v8
- Stage III Ovarian Cancer AJCC v8
- Stage III Pancreatic Cancer AJCC v8
- Stage III Primary Peritoneal Cancer AJCC v8
- Stage IV Fallopian Tube Cancer AJCC v8
- Stage IV Ovarian Cancer AJCC v8
- Stage IV Pancreatic Cancer AJCC v8
- Stage IV Primary Peritoneal Cancer AJCC v8
- Unresectable Breast Carcinoma
- Unresectable Fallopian Tube Carcinoma
- Unresectable Malignant Solid Neoplasm
- Unresectable Ovarian Carcinoma
- Unresectable Pancreatic Carcinoma
- Unresectable Primary Peritoneal Carcinoma
Interventions
- BIOLOGICAL: Dostarlimab
- DRUG: Niraparib
- PROCEDURE: Biopsy
- PROCEDURE: Biospecimen Collection
- PROCEDURE: Computed Tomography
- PROCEDURE: Magnetic Resonance Imaging
Sponsor
University of Washington
Collaborators